Stelara (Ustekinumab) Versus Etanercept for Psoriasis

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2010年 / 9卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：572 / 572
页数：1
相关论文
共 50 条
  • [41] Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
    van Muijen, Marloes E.
    Atalay, S.
    van Vugt, L. J.
    Vandermaesen, L. M. D.
    van den Reek, J. M. P. A.
    de Jong, E. M. G. J.
    DRUGS-REAL WORLD OUTCOMES, 2021, 8 (02) : 163 - 172
  • [42] Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study
    van Bezooijen, Ji Sun
    Balak, Deepak M. W.
    van Doorn, Martijn B. A.
    Looman, Caspar W. N.
    Schreurs, Marco W. J.
    Koch, Birgit C. P.
    van Gelder, Teun
    Prens, Errol P.
    DERMATOLOGY, 2016, 232 (04) : 407 - 414
  • [43] Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis
    Ferrandiz, C.
    Garcia, A.
    Blasco, A. J.
    Lazaro, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (06) : 768 - 777
  • [44] Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
    van der Schoot, L. S.
    Janssen, J. J.
    Bastiaens, M. T.
    de Boer-Brand, A.
    Christiaansen-Smit, C.
    Enomoto, D. N. H.
    Hovingh, R.
    Tupker, R. A.
    Seyger, M. M. B.
    Verhoef, L. M.
    van den Reek, J. M. P. A.
    de Jong, E. M. G. J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [45] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [46] Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
    Marloes E. van Muijen
    S. Atalay
    L. J. van Vugt
    L. M. D. Vandermaesen
    J. M. P. A. van den Reek
    E. M. G. J. de Jong
    Drugs - Real World Outcomes, 2021, 8 : 163 - 172
  • [47] Cost per treated patient for etanercept and ustekinumab in patients treated for moderate to severe plaque psoriasis
    Shah, Neel
    Harrison, David
    Wu, Ning
    Lee, Yuan-Chi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB166 - AB166
  • [48] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [49] CARDIOVASCULAR SAFETY OF USTEKINUMAB VERSUS ETANERCEPT IN PSORIASIS: RESULTS FROM AN OBSERVATIONAL POST-AUTHORIZATION SAFETY STUDY BASED ON SWEDISH NATIONAL REGISTERS
    Banefelt, Jonas
    Skroeder, Helena
    Azzabi, Ahlem
    Sheahan, Anna
    Suruki, Robert
    Geldhof, Anja
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [50] Etanercept in psoriasis
    Papp, KA
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) : 2139 - 2146
12345